MicroPort<sup>®</sup> EP's PathBuilder™ Steerable Introducer Wins Approval from National Medical Products Administration of China (NMPA)

Shanghai, China – On March 8, 2019, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") obtained a registration certificate from National Medical Products Administration of China (NMPA) for the independently developed PathBuilder™ Steerable Introducer.
 
The PathBuilder™ Steerable Introducer is comprised of an introducer, a dilator and a guide wire. It is a specialized device for use in the radiofrequency ablation procedure on the patients suffering cardiac arrhythmia. With a vascular access through the femoral vein, the PathBuilder™ Steerable Introducer introduces an ablation catheter or a mapping catheter to each cardiac chamber, including the left atrium using the atrial transseptal puncture procedure.
 
Previously, the PathBuilder™ Transseptal Introducer independently developed by MicroPort® EP had already been approved by NMPA to launch in China. The NMPA approval for PathBuilder™ Steerable Introducer is set to help MicroPort® EP provide the doctors and patients with better introducer options in the field of complex cardiac arrhythmia. In addition, the integrated electrophysiological solutions of MicroPort® EP, which combine active devices with passive devices and devices with equipment, will be further improved to benefit more Chinese cardiac arrhythmia patients.